Based on the technical indicators and recent analyst ratings, LH stock shows a neutral to slightly bullish outlook. The stock is currently trading at $245.08 with RSI at 56.84 indicating balanced momentum, while trading above its 20-day SMA of $243.81 suggests mild upward trend.

Recent analyst actions have been mostly positive, with Jefferies maintaining a Strong Buy rating and raising the price target to $290, while Barclays maintains a Hold rating with a $260 target. The consensus among analysts leans bullish, with multiple firms reiterating Buy ratings and price targets ranging from $260-$290.

The company's Q4 2024 results were encouraging, with adjusted EPS of $3.45 beating consensus of $3.39 and revenue growing 9.8% year-over-year to $3.33 billion. Management's 2025 guidance indicates continued growth with revenue projected at $13.9-$14.1 billion.

However, insider sentiment is notably negative, with 70 insiders selling shares recently, which warrants some caution. The most recent significant insider sale was by EVP Glenn Eisenberg who sold 11,711 shares in December 2024.

What is price prediction 2025 for LH Stock?

Based on recent analyst reports and technical analysis, Labcorp (LH) stock is projected to reach $275-285 by end of 2025, supported by strong Q4 2024 results and positive guidance for 2025. The company's strategic expansion in high-growth areas like oncology and women's health, combined with expected revenue growth of 6.5-7.7% in Diagnostics Laboratories segment, provides solid fundamentals for price appreciation. Multiple analysts including Truist Financial and Robert W. Baird maintain Buy ratings, though insider selling activity suggests some caution.

What is surpport and resistant level for LH Stock?

The S1 support level for LH Stock is $244.21 ,The R1 resistant level for LH Stock is $255.67.

What is the current price of LH Stock?

As of the end of day on 2025-02-12, the price of LH Stock was $242.75.

What is the target price of LH Stock?

The target price for LH Stock according to analyst rating is 275.38, with the highest price target at 290.00 and the lowest at 264.00. Analysts have a Strong Buy rating on LH Stock overall.

What is the market cap of Laboratory Corporation of America Holdings?

The market cap of LH is $20.4B.

Is Laboratory Corporation of America Holdings (LH) overvalued?

Based on the provided data and recent market analysis, here's an evaluation of LH's valuation:

Valuation Analysis: Laboratory Corporation shows declining profitability with net margin dropping from 7.19% to 4.31% over recent quarters, suggesting operational challenges. The P/E ratio has fluctuated significantly from 46.64 to 25.94 in Q4 2024, indicating high valuation volatility.

Recent Performance: Revenue growth remains positive with Q4 2024 revenue at $3.33 billion, showing a 9.8% year-over-year increase driven by 5.4% organic growth. However, net income has been declining sequentially from $228M in Q1 to $143.4M in Q4 2024.

Analyst Consensus: Wall Street maintains a Strong Buy rating with an average price target of $270.75, suggesting potential upside. Recent price target increases from multiple analysts, including Piper Sandler raising to $260 and Truist Financial maintaining a Buy rating at $285.

Market Position: The company holds approximately 20% of the independent lab market share and operates 2,000 patient-service centers, demonstrating strong market presence. Recent strategic moves into high-growth areas including oncology and women's health position it well for future growth.

Conclusion: With current EV/EBITDA of 11.96x and declining margins, LH appears fairly valued at current levels. While growth prospects remain solid, the declining profitability metrics and high valuation multiples suggest limited upside potential in the near term.

What is Laboratory Corporation of America Holdings (LH)'s business?

Laboratory Corporation of America Holdings provides comprehensive laboratory services that provides vital information to help doctors, hospitals, pharmaceutical companies, researchers, and patients make clear and confident decisions. By leveraging its unparalleled diagnostics and drug development capabilities, the Company provides insights and accelerates innovations to improve health and improve lives. The Company operates through two segments: Diagnostics Laboratories (Dx) and Biopharma Laboratory Services (BLS). The Diagnostics Laboratories segment includes routine testing and specialty/esoteric testing. Dx operates through a network of patient service centers, branches, rapid response laboratories, primary laboratories, and specialty laboratories. The Biopharma Laboratory Services segment consists of early development research laboratories and central laboratory services. The Company serves clients in more than 100 countries.

What is price prediction 2030 for LH Stock?

Based on analyst projections and market data, Labcorp (LH) stock is expected to reach approximately $290-300 by 2030, driven by strong growth in diagnostics business and strategic acquisitions in high-growth areas like oncology and women's health. The company's solid financial performance, with Q4 2024 beating expectations and positive 2025 guidance, supports this long-term growth trajectory. Multiple analysts maintain bullish ratings, with Jefferies recently raising their price target to $290, citing the diagnostics business providing insulation from broader healthcare volatility.